Novel TNF-α receptor 1 antagonist treatment attenuates arterial inflammation and intimal hyperplasia in mice.

AIM Tumor necrosis factor receptor 1 (TNFR1) participates importantly in arterial inflammation in genetically altered mice; however it remains undetermined whether a selective TNFR1 antagonist inhibits arterial inflammation and intimal hyperplasia. This study aimed to determine the effect and mechanism of a novel TNFR1 antagonist in the suppression of arterial inflammation. METHODS We investigated intimal hyperplasia in IL-1 receptor antagonist-deficient mice two weeks after inducing femoral artery injury in an external vascular cuff model. All mice received intraperitoneal injections of TNFR1 antagonist (PEG-R1antTNF) or normal saline twice daily for 14 days. RESULTS PEG-R1antTNF treatment yielded no adverse systemic effects, and we observed no significant differences in serum cholesterol or blood pressure in either group; however, selective PEG-R1antTNF treatment significantly reduced intimal hyperplasia (19,671±4,274 vs. 11,440±3,292 µm(2); p=0.001) and the intima/media ratio (1.86±0.43 vs. 1.34±0.36; p=0.029), compared with saline injection. Immunostaining revealed that PEG-R1antTNF inhibits Nuclear factor-κB (NF-κB), suppressing smooth muscle cell (SMC) proliferation and decreasing chemokine and adhesion molecule expression, and thus decreasing intimal hyperplasia and inflammation. CONCLUSIONS Our data suggest that PEG-R1antTNF suppresses SMC proliferation and inflammation by inhibiting NF-κB. This study highlights the potential therapeutic benefit of selective TNFR1 antagonist therapy in preventing intimal hyperplasia and arterial inflammation.

• Publication year

  2012

• Venue

  Journal of atherosclerosis and thrombosis

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.5551/JAT.9746PMID 22146239
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Absence of p55 TNF Receptor Reduces Atherosclerosis, but Has No Major Effect on Angiotensin II Induced Aneurysms in LDL Receptor Deficient Mice

  2009cited by this paper
• The treatment of established murine collagen-induced arthritis with a TNFR1-selective antagonistic mutant TNF.

  2009cited by this paper
• Vascular effects of biologic agents in RA and spondyloarthropathies

  2009cited by this paper
• P55 tumour necrosis factor receptor in bone marrow-derived cells promotes atherosclerosis development in low-density lipoprotein receptor knock-out mice.

  2008cited by this paper
• Creation and X-ray Structure Analysis of the Tumor Necrosis Factor Receptor-1-selective Mutant of a Tumor Necrosis Factor-α Antagonist*

  2008cited by this paper
• Cytokines and atherosclerosis: a comprehensive review of studies in mice

  2008cited by this paper
• TNFR1-induced NF-kappaB, but not ERK, p38MAPK or JNK activation, mediates TNF-induced ICAM-1 and VCAM-1 expression on endothelial cells.

  2007cited by this paper
• The role of TNF-alpha in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk.

  2007cited by this paper
• Expression of Tumor Necrosis Factor Receptor-1 in Arterial Wall Cells Promotes Atherosclerosis

  2007cited by this paper
• Tumor Necrosis Factor Receptor-2 Signaling Attenuates Vein Graft Neointima Formation by Promoting Endothelial Recovery

  2007cited by this paper
• Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.

  2006cited by this paper
• The effect of interleukin-1 receptor antagonist on arteries and cholesterol metabolism.

  2006cited by this paper
• Deficiency of Interleukin-1 Receptor Antagonist Deteriorates Fatty Liver and Cholesterol Metabolism in Hypercholesterolemic Mice*

  2005cited by this paper
• Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis.

  2005cited by this paper
• Involvement of Tumor Necrosis Factor-&agr; in the Development of T Cell–Dependent Aortitis in Interleukin-1 Receptor Antagonist–Deficient Mice

  2005cited by this paper
• This information is current as Infection Mycobacterium tuberculosis Control of and Provide Acute , but Not Long-Term , Cell Migration and Granuloma Formation Transmembrane TNF Is Sufficient to Initiate

  2005cited by this paper
• Lesion progression and plaque composition are not altered in older apoE-/- mice lacking tumor necrosis factor-alpha receptor p55.

  2004cited by this paper
• Site-specific PEGylation of a lysine-deficient TNF-alpha with full bioactivity.

  2003cited by this paper
• Inflammatory reactions in the pathogenesis of atherosclerosis.

  2003cited by this paper
• Tumor necrosis factor signaling

  2003cited by this paper
• Deficiency of Interleukin-1 Receptor Antagonist Promotes Neointimal Formation After Injury

  2003cited by this paper
• Site-specific PEGylation of a lysine-deficient TNF-α with full bioactivity

  2003cited by this paper
• Relative contribution of the TNF-alpha receptors to murine intimal hyperplasia.

  2003cited by this paper
• Relative contribution of the TNF-α receptors to murine intimal hyperplasia

  2003cited by this paper
• Anti–Tumor Necrosis Factor-&agr; Treatment Improves Endothelial Function in Patients With Rheumatoid Arthritis

  2002cited by this paper
• Transmembrane TNF Induces an Efficient Cell-Mediated Immunity and Resistance to Mycobacterium bovis Bacillus Calmette-Guérin Infection in the Absence of Secreted TNF and Lymphotoxin-α1

  2002cited by this paper
• TNF-R1 Signaling: A Beautiful Pathway

  2002cited by this paper
• Differential activation of nuclear factor‐κB by tumour necrosis factor receptor subtypes. TNFR1 predominates whereas TNFR2 activates transcription poorly

  2002cited by this paper
• Takayasu arteritis: a review.

  2002cited by this paper
• A new on-line dual enzymatic method for simultaneous quantification of cholesterol and triglycerides in lipoproteins by HPLC.

  2002cited by this paper
• Osteopontin Plays an Important Role in the Development of Medial Thickening and Neointimal Formation

  2002cited by this paper
• Anti–Tumor Necrosis Factor-α Treatment Improves Endothelial Function in Patients With Rheumatoid Arthritis

  2002cited by this paper
• Etk/Bmx as a Tumor Necrosis Factor Receptor Type 2-Specific Kinase: Role in Endothelial Cell Migration and Angiogenesis

  2002cited by this paper
• NF-kappaB: pivotal mediator or innocent bystander in atherogenesis?

  2001cited by this paper
• NF-κB: pivotal mediator or innocent bystander in atherogenesis?

  2001cited by this paper
• Atherosclerosis--an inflammatory disease.

  1999cited by this paper
• Production of Mice Deficient in Genes for Interleukin (IL)-1α, IL-1β, IL-1α/β, and IL-1 Receptor Antagonist Shows that IL-1β Is Crucial in Turpentine-induced Fever Development and Glucocorticoid Secretion

  1998cited by this paper
• Accelerated Atherosclerosis in Mice Lacking Tumor Necrosis Factor Receptor p55*

  1996cited by this paper
• The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor.

  1995cited by this paper
• Tumor necrosis factor alpha (TNF-alpha)-induced cell adhesion to human endothelial cells is under dominant control of one TNF receptor type, TNF-R55

  1993cited by this paper
• Syndromes of accelerated atherosclerosis: role of vascular injury and smooth muscle cell proliferation.

  1990cited by this paper
• The active form of tumor necrosis factor is a trimer.

  1987cited by this paper
• Molecular mechanism for feedback regulation of C4 biosynthesis in guinea pig peritoneal macrophage

  1984cited by this paper

• Deficiency of transcription factor E4BP4 suppresses neointimal formation after vascular injury.

  2026cites this paper
• Vascular smooth muscle cells in intimal hyperplasia, an update

  2023cites this paper
• Caloric restriction: Anti-inflammatory and antioxidant mechanisms against epileptic seizures.

  2022cites this paper
• Inhibition of TNFR1 Attenuates LPS Induced Apoptosis and Inflammation in Human Nucleus Pulposus Cells by Regulating the NF-KB and MAPK Signalling Pathway

  2021cites this paper
• TNF-α, TNF Receptors and Their Complex Implications in Therapy

  2020influential citation
• Outside-in signaling by femoral cuff injury induces a distinct vascular lesion in adipose triglyceride lipase knockout mice.

  2020cites this paper
• The Effects of Pro-Inflammatory and Anti-Inflammatory Agents for the Suppression of Intimal Hyperplasia: An Evidence-Based Review

  2020cites this paper
• Selective Targeting of TNF Receptors as a Novel Therapeutic Approach

  2020cites this paper
• Cases of intestinal smooth muscle hypertrophy/hyperplasia in pigeon and chickens

  2019cites this paper
• Improved monovalent TNF receptor 1-selective inhibitor with novel heterodimerizing Fc

  2019cites this paper
• Modulation of bioavailability of proinflammatory cytokines produced by myeloid cells.

  2019cites this paper
• Neuroinflammation impact in epileptogenesis and new treatment strategy.

  2019cites this paper
• Pathogenesis of fibrostenosing Crohn's disease.

  2019cites this paper
• Tumor Necrosis Factor Inhibition

  2018cites this paper
• A New Venue of TNF Targeting

  2018cites this paper
• Can we design a better anti‐cytokine therapy?

  2017cites this paper
• Therapeutic strategies for neurodegenerative disorders

  2017cites this paper
• Lobaric Acid Inhibits VCAM-1 Expression in TNF-α-Stimulated Vascular Smooth Muscle Cells via Modulation of NF-κB and MAPK Signaling Pathways

  2016cites this paper
• Anti-Inflammatory Small Molecules To Treat Seizures and Epilepsy: From Bench to Bedside.

  2016cites this paper
• Novel Immunotherapeutic Avenues for Rheumatoid Arthritis.

  2016cites this paper
• TNF biology, pathogenic mechanisms and emerging therapeutic strategies

  2016cites this paper
• Candidate drug targets for prevention or modification of epilepsy.

  2015cites this paper
• Targeting sTNF/TNFR1 Signaling as a New Therapeutic Strategy

  2015cites this paper
• Dipeptidyl‐Peptidase‐4 Inhibitor, Alogliptin, Attenuates Arterial Inflammation and Neointimal Formation After Injury in Low‐Density Lipoprotein (LDL) Receptor‐Deficient Mice

  2015cites this paper
• Inhibition of VCAM-1 expression on mouse vascular smooth muscle cells by lobastin via downregulation of p38, ERK 1/2 and NF-κB signaling pathways

  2015cites this paper
• Antibody-Mediated Inhibition of TNFR1 Attenuates Disease in a Mouse Model of Multiple Sclerosis

  2014cites this paper
• Inflammatory cytokines promote growth of intestinal smooth muscle cells by induced expression of PDGF-Rβ

  2014cites this paper
• Nonclinical Safety Biomarkers of Drug-induced Vascular Injury

  2014cites this paper
• TNF Receptor 2 and Disease: Autoimmunity and Regenerative Medicine

  2013cites this paper
• Antagonistic TNF Receptor One-Specific Antibody (ATROSAB): Receptor Binding and In Vitro Bioactivity

  2013cites this paper
• Tumor necrosis factor in traumatic brain injury : effects of genetic deletion of p 55 or p 75 receptor

  2013cites this paper
• Tumor Necrosis Factor in Traumatic Brain Injury: Effects of Genetic Deletion of p55 or p75 Receptor

  2013cites this paper
• A novel model of intimal hyperplasia with graded hypoosmotic damage.

  2012cites this paper
• Temporal Network Based Analysis of Cell Specific Vein Graft Transcriptome Defines Key Pathways and Hub Genes in Implantation Injury

  2012cites this paper
• Programa de Pós-Graduação em Análises Clínicas e Toxicológicas Área de Toxicologia e Análises Toxicológicas Efeitos dos ligantes de TSPO sobre a migração leucocitária: participação de receptores de glicocorticóides

  2012cites this paper